• Can Patients Skip Fasting With Higher Levothyroxine Dose?
• ATA Issues New Guidelines for Differentiated Thyroid Cancer
• Reducing MMI Dose Pre-Stop Cuts Relapse in Graves Disease
• GLP-1s Don’t Raise DTC Recurrence Risk, Study Says

Read Articles Now >>>

The post American Thyroid Association (ATA) 2025 Meeting In the News appeared first on American Thyroid Association.

Recently the FDA issued a statement of concern regarding the unregulated nature of these products and on August 6, 2025 sent letters to DTE manufacturers announcing their intention to ban DTE from the marketplace. In this communication, they suggested that patients work with their physicians to transition to FDA-approved products over a 12 month period. The ATA is aware that some patients taking DTE may not wish to transition to an alternative thyroid hormone replacement.

The FDA is now proposing that manufacturers of DTE submit an application through a regulatory pathway outlined under section 505 of the Federal Food, Drug, and Cosmetic (FD&C) Act, which applies to biologic products. The ATA supports evidence-based patient guidance, supported by high quality clinical research on the safety and efficacy of thyroid hormone replacement products. The ATA also supports regulations that ensure medication purity and consistency. The FDA’s identification of significant violations of current good manufacturing practice for DTE products is alarming. However, removal of the DTE from the marketplace during a potentially lengthy biologics license application would leave patients without access to DTE for an unknown period of time.

The ATA supports the principle of patient access to all safe and effective therapies for hypothyroidism. A regulatory approach that ensures the highest standards for DTE safety and reliability will ultimately benefit patients. The ATA is committed to working with the FDA, clinicians providing care for patients with hypothyroidism, patients, patient support organizations, and industry partners to ensure that safe and effective personalized hypothyroidism treatment remains available to all. The ATA is the leading professional medical society focused on thyroid diseases with recognized expertise in their treatment. The expertise of ATA was highlighted by the FDA in their recent statement. ATA’s vision, “Optimal Thyroid Health for All,” guides the organization in all areas, especially in the production of resources for clinicians and patients which are available through its website.

About the American Thyroid Association^® (ATA)
The ATA^® is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative and diverse community. ATA^® is an international professional medical society with over 1,700 members from seventy countries around the world.

The ATA^® promotes thyroid awareness and information through its online Clinical Thyroidology^® for the Public (distributed free of charge to over 12,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA^® website www.thyroid.org serves as a trusted clinical resource for patients and the public looking for reliable thyroid-related information.

The post American Thyroid Association Statement on Desiccated Thyroid Extract appeared first on American Thyroid Association.

Dr. Visser presented his research on “Understanding and Treating MCT8 Deficiency: From Mutation to Medicine,” on September 11th during the 94th ATA Annual Meeting in Scottsdale, Arizona. He is the division chief of Endocrinology at the Erasmus Medical Center in Rotterdam, The Netherlands and heads the Erasmus MC Thyroid Center, including the research laboratory.

Dr. Visser has great interest in understanding normal and disordered cellular thyroid hormone signaling. His research group performs translational and clinical studies in this field with particular interest in elucidating mechanisms of disease in MCT8 deficiency as well as developing a therapy. The ATA is honored to recognize Dr. Visser and his work with this prestigious award.

About the American Thyroid Association^® (ATA)
The ATA is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative and diverse community. ATA^® is an international professional medical society with over 1,700 members from seventy countries around the world.

The ATA® promotes thyroid awareness and information through its online Clinical Thyroidology^® for the Public (distributed free of charge to over 12,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA^® website  www.thyroid.org  serves as a trusted clinical resource for patients and the public looking for reliable thyroid-related information.

The post American Thyroid Association® Announces 2025 Van Meter Award appeared first on American Thyroid Association.

New Rochelle, NY, August 22, 2025—The American Thyroid Association has released new guidelines for the management of adult patients with differentiated thyroid cancer (DTC), the most prevalent cancer of the thyroid. The guidelines are published in the peer-reviewed journal Thyroid®, the official journal of the American Thyroid Association® (ATA®). Click here to read the article now.

The new guidelines, developed by an ATA task force led by Co-Chairs Matthew Ringel, MD, from The Ohio State University College of Medicine and Comprehensive Cancer Center, and Julie Ann Sosa, MD, from the University of California San Francisco, include input from a large, diverse complement of stakeholders. The panel included members from multiple specialties involved in thyroid cancer care, including a patient advocate and an expert in systematic reviews/meta-analyses/guidelines who educated and supported task force members. Jacqueline Jonklaas, MD, PhD, ATA President, noted that “ATA leadership is grateful to the task force members, ably lead by Drs. Ringel and Sosa, for this superlative clinical practice guideline that I believe will help set the standard of care for future generations of patients with thyroid cancer.”

These revised guidelines begin with the initial cancer diagnosis and continue with recommendations for staging and risk assessment; initial treatment decisions; assessment of treatment responses; monitoring approaches; diagnostic testing; and subsequent therapies based on the strength of evidence for response and consideration of side-effects and outcomes. Patient-reported outcomes, thyroid cancer survivorship, and identified areas of need for additional high-quality research are highlighted. “This thyroid cancer guideline continues the ATA’s leadership in providing high quality and evidence-based guidelines which provide thoughtful guidance to clinicians taking care of patients with thyroid cancer,” said Christopher McCabe, PhD, ATA Secretary and Chief Operating Officer.

About the Journal
Thyroid®, the official journal of the American Thyroid Association®, (ATA®) is an authoritative peer-reviewed journal published monthly online with open access options and in print. Led by Editor-in-Chief Anna M. Sawka, MD, PhD, University of Toronto, the Journal publishes original articles and timely reviews that reflect the rapidly advancing changes in our understanding of thyroid physiology and pathology, from the molecular biology of the cell to clinical management of thyroid disorders. Complete tables of content and a sample issue may be viewed on the Thyroid® website. The complete Thyroid Journal Program includes the highly valued abstract and commentary publication Clinical Thyroidology®, led by Editor-in-Chief Trevor E. Angell, MD and published monthly, and the groundbreaking videojournal companion VideoEndocrinology, led by Editor Catherine F. Sinclair, MD, FRACS. Complete tables of content and sample issues may be viewed on the Thyroid® website.

About the American Thyroid Association®
The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative and diverse community. ATA® is an international professional medical society with over 1,800 members from 43 countries around the world. The ATA® promotes thyroid awareness and information through Clinical Thyroidology®, a resource that summarizes research for patients and families, and extensive, authoritative resources on thyroid disease and thyroid cancer in both English and Spanish. The ATA® website www.thyroid.org serves as a bonafide clinical resource for patients and the public who look for reliable thyroid-related information.

About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.

The post New ATA Management Guidelines for Adult Patients with Differentiated Thyroid Cancer appeared first on American Thyroid Association.

Sonia Grandi, PhD
The Hospital for Sick Children; University of Toronto, Canada
Levothyroxine Initiation for Subclinical Hypothyroidism in Pregnancy And Neurodevelopmental and Cardiometabolic Outcomes in Children (LEARN)

2025 THYCA: THYROID CANCER SURVIVORS’ ASSOCIATION, INC. GRANT RECIPIENTS
Anastasios Maniakas, MD, PhD
University of Texas MD Anderson Cancer Center, United States
Decoding BRAF/MEK Resistance in Anaplastic Thyroid Cancer Through a Multi-Omic Longitudinal Interrogation Of Resistance Pathways: A PDX Model Approach

Nikhil Rammohan Assistant Professor MD, PhD
Washington University School of Medicine in St. Louis, United States
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) Combined with Targeted Systemic Therapy For Locally Advanced BRAF-V600E+ Anaplastic Thyroid Carcinoma

   
2025 BITE ME CANCER AND THYCA: THYROID CANCER SURVIVORS’ ASSOCIATION, INC. GRANT RECIPIENT
Tim Erickson, PhD
Earle A Chiles Research Institute at Providence Cancer Center, United States
Bispecific T Cell Engagers Targeting the MTC Surface Antigens CEA, GFRA4 and DLL3

The post 2025 Thyroid Research Grant Awardees Announced appeared first on American Thyroid Association.

The 2025 award winners are named below and will be honored during the ATA’s 2025 Annual Meeting to be held September 10 – 14, 2025 in Scottsdale, AZ.

“We are thrilled to recognize the exceptional achievements and leadership of these outstanding ATA members, whose accomplishments, innovation, and dedication reflect those of our incredible and diverse ATA community,” said Ari Wassner, MD, Chair of the Awards Committee.

The 2025 honorees are:

Susan J. Mandel, MD, MPH – Lewis E. Braverman Distinguished Lectureship Award

The Lewis E. Braverman Distinguished Lectureship Award recognizes an individual who has demonstrated excellence and passion for mentoring fellows, students and junior faculty, has a long history of productive thyroid research, and is devoted to the ATA. Dr. Mandel is Sylvan H Eisman Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at the Perelman School of Medicine, University of Pennsylvania. Her clinical practice focuses on thyroid neoplasia. Her research interests include sonography in the evaluation of patients with thyroid nodules and cancer. Dr. Mandel was on the writing groups for the 3 previous versions of the ATA Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and is co-chairing the 2025 ATA Guidelines for Patients with Thyroid nodules. She also was on the writing group for the ATA and Endocrine Society guidelines on the Management of Thyroid Disorders during Pregnancy. Dr. Mandel initiated and directed the Ultrasound workshops for the ATA and Endocrine Society. Dr. Mandel has received the Endocrine Society’s Distinguished Educator Award, the 2019 ATA WIT Woman of the Year award, and the AACE H. Jack Baskin Endocrine Teaching Award. She also received the Louis Duhring Outstanding Clinical Specialist Award from Penn Medicine. Dr. Mandel is past President of the Endocrine Society (2018-19) and of the Association of Program Directors in Endocrinology, Diabetes, and Metabolism (2009-2011). She currently serves as Secretary of the International Society of Endocrinology. During her 21-year tenure as Program Director of the Fellowship program at Penn, she trained over 70 fellows, eight of whom now serve as Endocrine Fellowship Program Directors. She has over 100 peer reviewed publications in journals including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. She has also authored chapters on thyroid disorders in Harrison’s Textbook of Medicine and thyroid nodules in Werner and Ingbar’s The Thyroid.

Kristien Boelaert, MD, PhD – Valerie Anne Galton Distinguished Lectureship Award

The Valerie Anne Galton Distinguished Lectureship Award recognizes an individual who has been instrumental in collaborative research that has significantly contributed to the advancement of our clinical knowledge of thyroid conditions. Dr. Boelaert is a Professor of Endocrinology at the University of Birmingham in the UK. She is an active researcher with an extensive portfolio spanning molecular, clinical and translational research into thyroid dysfunction, nodules and cancer. During her career she has attracted more than $12 million in research funding and published more than 200 research papers. In addition, Kristien is a prominent clinician who is actively involved in the setting of UK, European and ATA guidelines on the management of thyroid diseases. Recognizing her contributions to patient care, she was the recipient of the inaugural Outstanding Clinical Practitioner Award from the Society for Endocrinology in 2019. She is a strong believer in collaborative working and for many years has engaged closely with patient support organizations, policy makers and researchers in various disciplines across the world. Kristien has been an active member of the ATA since 2003, volunteering on several committees and currently serving as the co-chair of the ATA 2025 Annual Meeting. She has leadership roles in many international endocrine societies including President of the British Thyroid Association, Member of the European Thyroid Association Executive Committee and President Elect of the Society for Endocrinology.

Victor Joseph Bernet, MD, FACE, FACP – Distinguished Service Award

The Distinguished Service Award honors a member who has made important and continuing contributions to the American Thyroid Association (ATA). Dr. Bernet is the Director of the Mayo Clinic Endocrinology, Diabetes and Metabolism Fellowship in Jacksonville, Florida. He is a Professor of Medicine, Mayo Clinic College of Medicine and served as Chair of the Division of Endocrinology, Mayo Clinic Florida from 2012 to 2022. He is also an Adjunct Professor of Medicine, Uniformed Services University School of Medicine. Dr. Bernet served 21+ years in the U.S. Army Medical Corps retiring at the rank of Colonel. He was the Endocrinology Consultant to the Army Surgeon General and Director of the National Capitol Consortium Endocrinology, Diabetes and Metabolism Fellowship Program. Dr. Bernet is both a Distinguished Graduate and Distinguished Military Graduate of the Virginia Military Institute (1985). He graduated from the University of Virginia School of Medicine in 1989. He completed his internal medicine residency at Tripler Army Medical Center (1989-1992) and endocrinology fellowship at Walter Reed Army Medical Center (1992-1994). Dr. Bernet’s main academic interests are focused in the field of thyroid disorders with particular interest in thyroid nodules, thyroid cancer, challenging thyroid function tests as well as hormones found in OTC supplements. He has been the author/co-author of 70+ peer-reviewed articles and 19 book chapters. Dr Bernet served as President of the American Thyroid Association 2020-2021 and also as the ATA Secretary/ Chief Operating Officer from October 2015 to November 2019. Dr. Bernet serves as the Mayo Clinic representative on the National Comprehensive Cancer Network thyroid cancer guidelines and is a member of the ATA Thyroid Nodules Guidelines Task Force.

Paul M. Yen, MD – John B. Stanbury Thyroid Pathophysiology Medal

The John B. Stanbury Thyroid Pathophysiology Medal recognizes outstanding research contributions, either conceptual or technical, to the understanding of thyroid physiology or the pathophysiology of thyroid disease, as evidenced by having a major impact on research or clinical practice related to thyroid diseases. Dr. Yen is Professor at Duke-NUS Graduate Medical School in Singapore and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program. He also is Professor of Medicine at Duke University School of Medicine, Durham, NC and a member of the Duke Molecular Physiology Institute. He was formerly Assistant Professor at Harvard Medical School, Chief of the Neuro-endocrinology and Molecular Regulation Section of the Clinical Endocrinology Branch at NIDDK (at the National Institutes of Health, Bethesda, MD), and Associate Professor of Medicine and Pharmacology at Johns Hopkins University School of Medicine. He has served on the editorial boards of Endocrinology, Molecular Endocrinology, and Thyroid. He also is a U.S. board-certified physician in internal medicine and endocrinology. He is listed as a top 2% scientist worldwide by Stanford University and a leading World Expert on thyroid hormone by Expertscape. He has served as an Asia-Oceanic Thyroid Association (AOTA) Council Member and the AOTA delegate to the World Thyroid Foundation and Singapore Representative to the International Iodine Global Network. He was awarded the 2020 Nagataki-Fujifilm Prize for his contributions to basic and clinical thyroid hormone research in Asia by AOTA. At Duke-NUS, he has served as Master of Sheares Medical College since 2010. He also has served as the clinical faculty advisor for the Duke Overseas Volunteer Expedition (DOVE) program in which medical students deliver primary care in neighbouring underdeveloped countries since its inception in 2010. His laboratory uses molecular biological and genomic approaches to study hormonal regulation of transcription, autophagy, and metabolism as well as searching for ways to improve the diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD).

Thomas S. Scanlan, PhD – Sidney H. Ingbar Distinguished Lectureship Award

Sidney H. Ingbar Distinguished Lectureship Award recognizes outstanding academic achievements in thyroidology, in keeping with the innovation and vision that epitomized Dr. Ingbar’s brilliant investigative career. The Ingbar award is conferred upon an established investigator who has made major contributions to thyroid-related research over many years. Dr. Scanlan is Professor of Physiology & Pharmacology in the Department of Chemical Physiology & Biochemistry at Oregon Health & Science University (OHSU) in Portland, Oregon.  Before that he was Professor of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology at the University of California, San Francisco (UCSF).  Dr. Scanlan’s formal training is in organic chemistry, and in 1991 he began his independent career using chemical approaches to study thyroid hormone action.  Dr. Scanlan’s research accomplishments include the discovery and development of selective thyromimetics, most notably Sobetirome (GC-1) which has been studied clinically for different metabolic disease indications. Dr. Scanlan also discovered and characterized a novel class of biogenic amine thyroid hormone metabolites called thyronamines that have biological activities distinct from those of thyroxine and T₃.  Most recently Dr. Scanlan’s research has focused on the development of central nervous system penetrating thyromimetics, one of which is currently in clinical development for depression.  Dr. Scanlan has over 14,000 career citations and an h-index of 63. His honors include the National Science Foundation Career Award, the Alfred P. Sloan Research Fellow Award, the Arthur C. Cope Scholar Award from the American Chemical Society, the Resko Faculty Research and Mentoring Award, and the Technology Transfer Achievement Award (OHSU).

.

Angela M. Leung, MD – Women in Thyroidology Woman of the Year

The Women in Thyroidology Woman of the Year Award recognizes an ATA member who is dedicated to the field and the advancement of women in thyroidology. Dr. Leung is a Health Sciences Associate Clinical Professor of Medicine in the Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine at the University of California Los Angeles David Geffen School of Medicine and the VA Greater Los Angeles Healthcare System. Dr. Leung received her undergraduate degree from Occidental College, her MD from the Boston University School of Medicine, and MSc in Epidemiology from the Boston University School of Public Health. She completed her internal medicine internship and residency and endocrinology fellowship at Boston University School of Medicine/Boston Medical Center. Her clinical and research interests are focused on thyroid disease and include iodine nutrition, environmental thyroid disruptors, and maternal-child thyroid health. She has served on the ATA writing committees of the thyroid eye disease consensus statement, the updated differentiated thyroid cancer guidelines, and is co-chair of the updated thyroid and pregnancy guidelines. Dr. Leung has served on the ATA Board of Directors, Editor-in-Chief of Clinical Thyroidology^® and as Chair of the Women in Thyroidology.

About the American Thyroid Association^®

The American Thyroid Association (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative and diverse community. ATA^® is an international professional medical society with over 1,700 members from 70 countries around the world. The ATA^® promotes thyroid awareness and information through Clinical Thyroidology^® for the Public, a resource that summarizes research for patients and families, and extensive, authoritative resources on thyroid disease and thyroid cancer in both English and Spanish. The ATA^® website www.thyroid.org serves as a bonafide clinical resource for patients and the public who look for reliable thyroid-related information.

The post American Thyroid Association® Announces 2025 Award Winners appeared first on American Thyroid Association.

Join us in celebrating our collective impact as we review key highlights and contributions to this vital mission. Let’s keep pushing boundaries and elevating thyroid health in 2025 – because together, we’re stronger!

Clinical Excellence

• Complimentary Graves’ Disease: Surgery and Beyond webinar hosted by ATA^®, in collaboration with American Association for Endocrine Surgeons, and the American Head & Neck Society. View the recording here.
• New – Ablation Techniques for Benign Thyroid Nodules Guidelines Pocket Guide
• ATA^® and Medscape collaboration resulting in eight episodes in the series:  Thyroid Stimulating Podcasts with ATA member contributor Kaniksha Desai, MD
• Ongoing work to bring forward the latest guidelines in essential areas:
  • Differentiated Thyroid Cancer Guidelines Update
  • Thyroid & Pregnancy Guidelines Update
  • Thyroid Nodules Guidelines
  • MTC Guidelines Update: Systemic Therapies

Continue reading more highlights and contributions in 2024…

The post 2024: ATA® Year in Review appeared first on American Thyroid Association.

Washington, D.C. – Wednesday, U.S. Representative Haley Stevens (D-MI) introduced the Thyroid Disease CARE Act and hosted a press conference on the House steps to raise awareness about the disparities in the research and treatment of thyroid disorders which disproportionately affect women.

“1 in 8 American women will develop thyroid issues in their lifetimes,” said Rep. Haley Stevens (D- MI). “That’s why I introduced the Thyroid Disease CARE Act this week – to infuse $30 million in research funding through the Department of Health and Human Services to explore why women are disproportionately impacted by thyroid disease. Health issues specific to or more prevalent in women have historically been overlooked and under researched and with women making up more than half the population, it’s high time to right this wrong.”

“As a physician who treats thyroid disorders and sees their impact on patients’ lives, I understand the need for greater insight into their causes and for advances in our tools to diagnose and treat them. More funding for thyroid research is long overdue.” said Dr. Paul Ladenson. “That’s why I was thrilled to join Congresswoman Haley Stevens this week at the U.S. Capitol in support of the Thyroid Disease CARE Act. It’s time for more Federal resources to be directed to understanding and managing a set of diseases that affect so many Americans, especially women.”

“As a thyroid cancer survivor, I know very deeply the urgent need for research into thyroid disease,” said Bryn Silverman, advocate and filmmaker. “So often our experiences as people living with thyroid disease are misdiagnosed or not diagnosed at all; our quality of life is undervalued and our symptoms are overlooked. The Thyroid Disease CARE Act has the potential to change thousands of people’s lives and expand the vocabulary we as patients have to make informed decisions about our healthcare.”

Watch the press conference in full here.

###

The post Rep. Haley Stevens (D-MI) Introduces Legislation to Address the Major Disparities in Research on Thyroid Disorders Which Affect 1 in 8 American Women appeared first on American Thyroid Association.

The ATA is delighted to recognize 2024 Van Meter Award winner Carla Moran, MB BCh, BAO, PhD. She is the first award winner from Ireland and a noted international thyroid researcher. Dr. Moran presented on “Advances in Diagnosis, Phenotyping and Management of Resistance to Thyroid Hormone.”

Dr. Moran is Associate Professor and Consultant Endocrinologist at Beacon Hospital and Honorary Consultant Endocrinologist at St. Vincent’s University Hospital, both in Dublin, Ireland. She is also Associate Professor at University College Dublin School of Medicine.

The Van Meter Award Lecture, established in 1930, recognizes outstanding contributions to research on the thyroid gland or related subjects. The award is given each year to an investigator who is not older than the age of 45 in the year of the award. The Van Meter award winner is kept secret until the time of the award lecture during the ATA Annual Meeting.

About the American Thyroid Association^® (ATA)

The ATA is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative and diverse community. ATA^® is an international professional medical society with over 1,700 members from 70 countries around the world.

The ATA^® promotes thyroid awareness and information through its online Clinical Thyroidology® for the Public (distributed free of charge to over 12,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA^® website www.thyroid.org serves as a bonafide clinical resource for patients and the public who look for reliable thyroid-related information.

The post American Thyroid Association® Announces 2024 Van Meter Award appeared first on American Thyroid Association.

“I am honored to contribute to the society that has been my professional home for so many years by serving as its current President,” said Jacqueline Jonklaas, MD, PhD.

The 16-member Board will also have three new directors, Elizabeth Grubbs, MD, Cari Kitahara, PhD, and Maya Lodish, MD, and two trainee observers, Kharisa Rachmasari, MD, and Freddy Toloza Bonilla, MD. Congratulations to all!

ATA thanks the Nominating Committee, chaired by Martha Zeiger, MD, and the members with a desire to serve in leadership, including those nominated and those who ran for election. And ATA recognizes the service of  the members who are rotating off the Board of Directors this year:  Amy Chen, MD, Aime Franco, PhD, Celeste Hart, MD, Sareh Parangi, MD, Mona Sabra, MD, Julie Ann Sosa, MD, Martha Zeiger, MD, Brandon Moretti, MD, and David Toro-Tobon, MD.

Officers

President
Jacqueline Jonklaas, MD, PhD is Professor of Endocrinology at Georgetown University. Her area of particular interest is hypothyroidism and thyroid cancer. Dr. Jonklaas enjoys dividing her time between research, clinical activities, and teaching. Dr. Jonklaas has published research regarding treatment and outcomes in patients with thyroid cancer. She has also studied therapy for hypothyroidism and was the co-lead of the ATA’s 2014 guidelines for the treatment of hypothyroidism. She participates in translational research and is the director of the Georgetown Clinical Research Unit.

Dr. Jonklaas has been a member of the ATA since 1999, serves on the editorial board of the journal Thyroid^®, and recently completed a term as ATA Secretary. She was Co-chair of the ATA Task Force on Thyroid Hormone Replacement and Co-chair of the inaugural Guidelines and Statements Committee. Being a member of the ATA has been an integral and invaluable part of Dr. Jonklaas’ professional development.

President-Elect
M. Regina Castro, MD is Professor of Medicine, and Consultant in Endocrinology & Metabolism at Mayo Clinic, Rochester where she currently serves as the Director for the Endocrinology fellowship program. She is a clinician, educator, and clinical investigator. Her main areas of interest include the evaluation of patients with thyroid disorders, especially thyroid nodules and thyroid cancer.

Dr. Castro has been an active member of the ATA since 2000, serving on multiple committees:  Board of Directors (2014-1028), Patient Affairs and Education Committee (Chair, Co-chair), Website Advisory Committee,  Editorial Board of Clinical Thyroidology® for the Public, Trainees & Career Advancement Committee, Diversity, Equity and Inclusion Task Force (Co-chair) and the Publications Committee.  As Chair of the Patient Affairs and Education committee she led the effort to develop bilingual patient education materials and to organize the Annual ATA Patient Forum. She has participated in multiple ATA meetings as a speaker, 2018 Program Co-chair, and recipient of the 2023 Distinguished Service Award. She also served as Women in Thyroidology (WIT) President and Past President (2019-2021) and received the WIT Woman of the Year Award (2022).

Treasurer-Elect
Mark Zafereo, MD, is Professor of Head and Neck Surgery at MD Anderson Cancer Center in Houston, Texas, where he is Section Chief of Head and Neck Endocrine Surgery and Associate Medical Director of the Head & Neck Center. His clinical practice and research focuses on patients afflicted with thyroid cancer and parathyroid neoplasms, particularly multidisciplinary care of patients with advanced thyroid cancer, wherein he leads several national multicenter clinical trials on neoadjuvant therapy followed by surgery.

Dr. Zafereo has served on multiple ATA committees and task forces, including the Internet Communications Committee; the Leadership Strategic Planning Retreat; the Surgical Affairs Committee (currently Chair); the Education and Outreach Task Force, the Spring Meeting Program Committee, and the Medullary Thyroid Cancer Guidelines Task Force. He also serves on the Editorial Board and as an Associate Editor for Thyroid®.

Directors

Elizabeth Grubbs, MD is Professor and Surgical Endocrinologist at the University of Texas MD Anderson Cancer Center. She also serves as Director of Faculty Academic Career Development for the institution’s 2000+ faculty members and Co-faculty Director of its Leadership Institute. Dr. Grubbs specializes in the surgical treatment of both benign and malignant conditions of the thyroid. She is the founder of the Medullary Thyroid Cancer Collaborative Registry (MTCCoRe), a multi-institutional effort.

Dr. Grubbs has been an active member of the ATA since 2012. She served as the Program Committee Co-chair for the Centennial 2023 ATA Annual Meeting in Washington, D.C. She is a member of the writing taskforce for the Differentiated Thyroid Cancer Guidelines and a past member of both the Surgical Affairs and Trainee and Career Advancement Committees. She serves as the ATA liaison to the American Association of Endocrine Surgeons.

Cari Kitahara, PhD, MHS, is a Senior Investigator in the Radiation Epidemiology Branch of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland. Dr. Kitahara leads multidisciplinary research programs focused on thyroid cancer etiology and survivorship and radiation-associated health risks to medical staff and patients. Her work, including nearly 200 peer-reviewed publications and six book chapters, provides rigorous and high-quality evidence to inform cancer prevention efforts, radiation protection practices, and patient care.

Dr. Kitahara has been an active member of the ATA since 2018, serving  on the Public Health Committee in 2020 and the Program Committee from 2020-2023. She joined the Editorial Board of the journal Thyroid® in 2018 and continues in that role. She was the 2019 recipient of the ATA’s Van Meter Award.

Maya Lodish, MD, MHSc, holds the Selna L. Kaplan Chair as Distinguished Professor of Pediatric Endocrinology and Division Chief of Pediatric Endocrinology at the University of California San Francisco. Her research interests are in the endocrine-related complications faced by survivors of pediatric cancers, as well as in the genetic etiologies of pediatric endocrine tumors. She plays a leading role in several studies to understand the pathophysiology and to improve the clinical care for pediatric patients with endocrine tumors.  Dr. Lodish also leads endocrine care and clinical research in the UCSF cancer survivor multidisciplinary clinic, and the Pediatric Hereditary Cancer Clinic.

Dr. Lodish has been an ATA member since 2018 and has served on the ATA Education Leadership Committee (2020-2022).

Kharisa Rachmasari, MD is Assistant Professor at Mayo Clinic, currently transitioning from her endocrinology fellowship at Mayo Clinic, Rochester, to become a consultant at Mayo Clinic Health System in La Crosse, WI. She is passionate about thyroid disorders, including thyroid nodules, thyroid autoimmunity and thyroid cancer, and has published research in those topics. She has also written review articles in Clinical Thyroidology®.

Dr. Rachmasari completed medical school at Weill Cornell Medicine in Qatar, internal medicine residency at New York Presbyterian-Cornell, New York, and a 3-year endocrinology fellowship at Mayo Clinic Rochester, MN. Currently, she is part of the ATA Trainee and Career Advancement Committee, including involvement in the E. Chester Ridgway Trainee Conference.

Freddy Toloza Bonilla, MD, is an adult endocrinology fellow at the National Institutes of Health in Bethesda, MD. He has several publications on thyroid functional disorders and has served as an ad-hoc reviewer for multiple journals, including Thyroid®.

Dr. Toloza Bonilla attended Universidad de los Andes in Bogota, Colombia. He completed internal medicine residency at Metrowest Medical Center in Framingham, MA, and two years of clinical research training focused on thyroid functional disorders at Mayo Clinic, Rochester, and the University of Arkansas for Medical Sciences in Little Rock. Since joining the ATA in 2019, Dr. Toloza Bonilla has engaged in numerous educational opportunities. He is committed to enhancing interest in thyroidology among trainees and increasing the number of ATA in-training members.

The American Thyroid Association^® (ATA^®) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery, and advocacy in a collaborative community. ATA is an international professional medical society with more than 1,700 members from 70 countries around the world.

The ATA promotes thyroid awareness and information through its online Clinical Thyroidology® for the Public (distributed free of charge to over 12,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA® website www.thyroid.org serves as a bonafide clinical resource for patients and the public who look for reliable information on the Internet.

###

The post American Thyroid Association® Announces 2024-2025 Officers and Board of Directors appeared first on American Thyroid Association.